Press Release Archives - Page 21 of 24

Spectral Medical Announces Report on Clinical Implementation of SAMI Amid COVID-19 Published in the Journal of Blood Purification

Operating the SAMI viewed as both simple and safe by the nurses Successful remote deployment of SAMI with only 3 hours of virtual training Toronto, Ontario | November 11, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...

Spectral and Dialco Sponsored Symposiums at the 38th Vicenza Course on AKI and CRRT

Toronto, Ontario | November 3, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical In. (“Dialco”), are pleased to announce the following sponsored symposiums at the virtual 38th Vicenza Course on AKI and...

Spectral to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

TORONTO, Canada – September 8, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), announced today that Dr. Paul Walker, Spectral’s Chief Executive Officer and Chris Seto, Spectral’s Chief Operating and Chief Financial Officer will be presenting...

U.S. FDA Grants 510(k) Clearance for Spectral’s DIMI

Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities U.S. skilled nursing facilities market represents an estimated US$2 billion market annually TORONTO, Canada – August 31, 2020 – Spectral Medical Inc. (“Spectral” or the...

US FDA Approves Spectral Medical’s Protocol Amendment for TIGRIS

Protocol Amendment allows for increase in TIGRIS sites to 15 while potentially accelerating patient enrolling and offsetting any COVID-19 pandemic-related delays Toronto, Ontario | August 10, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a...

Spectral Medical Provides Corporate Update

Early Tigris trial observations in-line with Euphrates post-hoc results Investigator-driven studies show endotoxin levels significantly elevated in most patients with COVID-induced septic shock Q4 2020 EAA multi-country European launch DIMI traditional FDA 510(k)...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.